Q3 2024 Rhythm Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Rhythm Pharmaceuticals Inc (RYTM) reported strong revenue growth with third-quarter revenues reaching $33.3 million, a 14% increase from the previous quarter.
- The company is making significant progress in its clinical programs, with the phase three trial for hypothalamic obesity on track for a data readout in the first half of 2025.
- Real-world data from France showed promising results for hypothalamic obesity patients, with a mean BMI decrease of 21.3% at six months.
- The company is expanding its market presence internationally, with INSR now available in over 15 countries outside the United States.
- Rhythm Pharmaceuticals Inc (RYTM) has reduced its 2024 operating expense guidance, indicating improved operating leverage and financial management.
- The company experienced a slight increase in cost of sales, primarily due to higher labor and overhead costs.
- There is a noted dropout rate in clinical trials, although it remains below 10%, which could impact future trial outcomes.
- The company faces challenges in enrolling patients for certain substudies, such as LE R and SRC one, which may delay progress.
- Despite strong growth, there is still a significant portion of prescriptions transitioning to free drug due to lack of coverage, particularly from Medicare.
- The company acknowledges the need for better identification of patients with true loss of function variants, which could complicate future development efforts.
Good day. And thank you for standing by. Welcome to the Rhythm Pharmaceuticals third quarter, 2024 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session to ask a question during the session. You will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised to withdraw your question. Please press star 11 again.
Please advise that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, David Connolly, head of Investor relations and corporate communications. Please go ahead.
Thank you, Shannon. I'm Dave Connelly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the investors section of our website, Ir dot rhythmtx dotcom.
This afternoon, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
